HK1016410A - Stable liquid preparation of a vitamin complex for internal use - Google Patents
Stable liquid preparation of a vitamin complex for internal use Download PDFInfo
- Publication number
- HK1016410A HK1016410A HK98117862.2A HK98117862A HK1016410A HK 1016410 A HK1016410 A HK 1016410A HK 98117862 A HK98117862 A HK 98117862A HK 1016410 A HK1016410 A HK 1016410A
- Authority
- HK
- Hong Kong
- Prior art keywords
- vitamin
- preparation
- liquid preparation
- internal use
- complex
- Prior art date
Links
Description
This invention relates to a stable liquid preparation of complex vitamin for internal use, and more specifically to a liquid preparation of complex vitamin for internal use, which remains stable even when stored for a long period at room temperature.
Like vitamin B₆, vitamin B₁ and vitamin B₁₂ are closely associated with nervous functions and are effective for the improvement of neuroses such as neuralgia, arthralgia, peripheral neuritis and peripheral paralysis. A variety of tablets and capsules added with these vitamins are therefore available on the market.
As a dosage form, a liquid preparation generally features that compared with such tablets and capsules, the liquid preparation is more readily absorbed in the body and is easier to take. Nonetheless, no stable liquid preparation added with both vitamin B₁ and vitamin B₁₂ has been available on the market. This is attributed to the poor storage stability of a liquid preparation containing both of them.
As causes for the poor storage stability of the liquid preparation added with both vitamin B₁ and vitamin B₁₂, it is known that the stable pH ranges of these vitamins in an aqueous solution are different, i.e., pH 2-4 for vitamin B₁ and pH 4.5-5 for vitamin B₁₂ and also that SH-containing decomposition products of vitamin B₁ extremely lower the stability of vitamin B₁₂.
Further, sucrose is generally used as a sweetening agent in liquid preparations for internal use. Sucrose may however lower the stability of vitamin B₁ and vitamin B₁₂, depending on its concentration and the pH. Liquid preparations for internal use are also added with a corrigent, a flavoring agent, a buffer agent, a preservative and the like. These additives may also give adverse effects on the stability, thereby making it more difficult to formulate a liquid preparation for internal use, which contains vitamin B₁ and vitamin B₁₂.
An object of the present invention is therefore to provide a liquid preparation for internal use, which contains vitamin B₁ and vitamin B₁₂ and remains stable even when stored for a long period at room temperature.
With the foregoing circumstances in view, the present inventors have proceeded with extensive research. As a result, it has been found that the above-described problem can be overcome by the addition of vitamin B₁ and vitamin B₁₂ to a particular solution base, leading to the completion of the present invention.
In one aspect of the present invention, there is thus provided a stable liquid preparation of complex vitamin for internal use, said preparation containing vitamin B₁ and vitamin B₁₂, comprising a sugar alcohol as a sweetening agent, the pH of said preparation having been adjusted to 3.5 to 4.5.
In the liquid preparation of complex vitamin for internal use according to the present invention, the activities of vitamin B₁ and vitamin B₁₂ are stably maintained without reduction even when the liquid preparation is stored for a long period at room temperature.
In the present invention, examples of vitamin B₁ include thiamine and thiamine derivatives such as fursultiamine, octotiamine, thiamine disulfide, bisbentiamine, bisbutitiamine, bisibutiamine and benfotiamine as well as their salts. Their hydrochlorides, nitrates and the like can be mentioned as these salts. Vitamin B₁ can preferably be added in an amount of 1-50 mg per 50 mℓ of the liquid preparation of complex vitamin for internal use (hereinafter called "the present preparation").
On the other hand, cyanocobalamin is preferred as vitamin B₁₂. It is preferred to add it in an amount of 1-5,000 µg in the present preparation.
Illustrative sugar alcohols usable as sweetening agents in the present invention include xylitol, maltitol and sorbitol. Since these sugar alcohols have the merit that they are hardly digestible and do not raise the blood sugar level, they are advantageous particularly for those suffering from diabetes mellitus or obesity. The sugar alcohol can be added preferably in an amount of 0.5-20 g, notably 1-15 g in the present preparation.
The above sugar alcohol has lower sweetness compared with sucrose, so that sucrose can be added to the liquid preparation of complex vitamin for internal use according to the present invention to supplement the sweetness. From the standpoint of stability of both the vitamins, it is necessary to limit the amount of added sucrose below 5 g in the present preparation.
As a pH regulator for adjusting the pH to 3.5-4.5 in the present invention, it is preferred to use an organic acid such as citric acid, malic acid, tartaric acid or succinic acid or a salt thereof which can reduce the bitterness of added ingredients and can make the preparation easier to take, although hydrochloric acid, sodium hydroxide or the like may be used. Regarding the amount of such an organic acid or a salt thereof in the liquid preparation of complex vitamin for internal use, it is preferred to limit its amount below 0.5 g in the present preparation.
In addition to the above-described essential ingredients, the liquid preparation of complex vitamin for internal use according to the present invention can be added, as needed, with optional ingredients, for example, drug efficacy ingredients such as B₂ vitamins, B₆ vitamins, E vitamins, nicotinic acid, nicotinamide, pantothenic acids, pantothenol, aminoethylsulfonic acid, anhydrous caffeine, γ-oryzanol, and crude drug ingredients, e.g., ginseng; solubilizers such as ethanol and polyoxyethylene-hydrogenated castor oil; preservatives such as benzoic acid and alkyl parabens (i.e., alkyl parahydroxybenzoates); coloring agents such as caramel; and perfumes.
The present invention will hereinafter be described in further detail by the following Examples, Comparative Examples and Test. It should however be borne in mind that the present invention is not limited to them in any way whatsoever.
The ingredients indicated in Table 1 were weighed in the amounts specified there and were then dissolved in purified water to give a total volume of 20 mℓ. The resulting solution was filtered through a 0.45-µm membrane filter and filled in a 20-mℓ amber-colored glass bottle. The glass bottle was plugged and then subjected to sterilization at 80°C for 20 minutes, whereby a liquid preparation of complex vitamin for internal use was produced.
Incidentally, thiamine nitrate and cyanocobalamin were added 115% on their indicated amounts.
Table 1
| Thiamine nitrate | 10 mg |
| Cyanocobalamin | 1,500 µg |
| Pyridoxine hydrochloride | 100 mg |
| Nicotinamide | 50 mg |
| Pantothenol | 30 mg |
| D-Sorbitol solution (70%) | 2,000 mg |
| Xylitol | 2,500 mg |
| Malic acid | 20 mg |
| Sodium hydroxide | Sufficient to adjust the pH to 4.0 |
| Sodium benzoate | 14 mg |
| Butyl parahydroxybenzoate | 1 mg |
| Caramel | 100 mg |
| Perfume | trace |
| Purified water | Sufficient to produce 20 mℓ |
Following the procedures of Example 1, a liquid preparation of complex vitamin for internal use was produced in accordance with the formulation shown in Table 2.
Table 2
| Thiamine nitrate | 10 mg |
| Cyanocobalamin | 1,500 µg |
| Pyridoxine hydrochloride | 50 mg |
| Nicotinamide | 60 mg |
| Pantothenol | 15 mg |
| D-Sorbitol solution (70%) | 3,000 mg |
| Maltitol solution (75%) | 4,000 mg |
| Citric acid | 80 mg |
| Sodium citrate | Sufficient to adjust the pH to 4.0 (15 mg) |
| Sodium benzoate | 35 mg |
| Butyl parahydroxybenzoate | 4 mg |
| Caramel | 50 mg |
| Perfume | trace |
| Purified water | Sufficient to produce 50 mℓ |
Following the procedures of Example 1, a liquid preparation of complex vitamin for internal use was produced in accordance with the formulation shown in Table 3.
Table 3
| Fursultiamine hydrochloride | 6 mg |
| Cyanocobalamin | 1,500 µg |
| Pyridoxine hydrochloride | 10 mg |
| Riboflavin sodium phosphate | 5 mg |
| Nicotinamide | 25 mg |
| Anhydrous caffeine | 50 mg |
| Aminoethylsulfonic acid | 1,000 mg |
| D-Sorbitol solution (70%) | 7,000 mg |
| Purified sucrose | 4,000 mg |
| Citric acid | 200 mg |
| Sodium citrate | Sufficient to adjust the pH to 3.7 (120 mg) |
| Sodium benzoate | 35 mg |
| Butyl parahydroxybenzoate | 4 mg |
| Caramel | 5 mg |
| Perfume | trace |
| Purified water | Sufficient to produce 50 mℓ |
Following the procedures of Example 1, a liquid preparation of complex vitamin for internal use was produced in accordance with the formulation shown in Table 4.
Table 4
| Fursultiamine hydrochloride | 6 mg |
| Cyanocobalamin | 1,500 µg |
| Pyridoxine hydrochloride | 10 mg |
| Nicotinamide | 50 mg |
| Anhydrous caffeine | 50 mg |
| Liquid ginseng extract | 0.6 mℓ |
| Liquid polygonati rhizoma extract | 0.4 mℓ |
| Liquid cistanchis herba extract | 0.3 mℓ |
| D-Sorbitol solution (70%) | 5,000 mg |
| Xylitol | 1,500 mg |
| Purified sucrose | 2,000 mg |
| Citric acid | Sufficient to adjust the pH to 4.2 (100 mg) |
| Sodium citrate | 120 mg |
| Polyoxyethylene-hydrogenated castor oil 60 | 10 mg |
| Sodium benzoate | 35 mg |
| Butyl parahydroxybenzoate | 4 mg |
| Caramel | 5 mg |
| Perfume | trace |
| Purified water | Sufficient to produce 50 mℓ |
Following the procedures of Example 1, a liquid preparation of complex vitamin for internal use was produced in accordance with the formulation shown in Table 5.
Table 5
| Thiamine nitrate | 10 mg |
| Cyanocobalamin | 1,500 µg |
| Pyridoxine hydrochloride | 50 mg |
| Nicotinamide | 60 mg |
| Pantothenol | 15 mg |
| Purified sucrose | 2,000 mg |
| Isomerized sugar | 6,500 mg |
| Citric acid | 80 mg |
| Sodium citrate | Sufficient to adjust the pH to 4.0 |
| Sodium benzoate | 35 mg |
| Butyl parahydroxybenzoate | 4 mg |
| Caramel | 50 mg |
| Perfume | trace |
| Purified water | Sufficient to produce 50 mℓ |
Following the procedures of Example 1, a liquid preparation of complex vitamin for internal use was produced in accordance with the formulation shown in Table 6.
Table 6
| Thiamine nitrate | 10 mg |
| Cyanocobalamin | 1,500 µg |
| Pyridoxine hydrochloride | 50 mg |
| Nicotinamide | 60 mg |
| Pantothenol | 15 mg |
| Purified sucrose | 7,500 mg |
| Citric acid | 250 mg |
| Sodium citrate | Sufficient to adjust the pH to 5.0 |
| Sodium benzoate | 35 mg |
| Butyl parahydroxybenzoate | 4 mg |
| Caramel | 50 mg |
| Perfume | trace |
| Purified water | Sufficient to produce 50 mℓ |
The liquid preparations of complex vitamin for internal use, which had been produced in Examples 1-4 and Comparative Examples 1-2, respectively, were stored at room temperature for 12 months and 24 months, followed by quantitative analyses of vitamin B₁ and vitamin B₁₂. The results of the stability test of vitamin B₁ are shown in Table 7, whereas the results of the stability test of vitamin B₁₂ are presented in Table 8.
The quantitative analyses were conducted by high performance liquid chromatography, and the stability of each liquid preparation is indicated by a value (%) on the indicated amount.
| After stored for 12 months | After stored for 24 months | |
| Example 1 | 107.7 | 100.7 |
| Example 2 | 108.8 | 100.8 |
| Example 3 | 110.9 | 104.1 |
| Example 4 | 109.6 | 102.7 |
| Comp.Ex. 1 | 104.5 | 95.2 |
| Comp.Ex. 2 | 96.3 | 78.9 |
| At the time of production: 115.0% | ||
| After stored for 12 months | After stored for 24 months | |
| Example 1 | 104.2 | 93.7 |
| Example 2 | 105.8 | 96.0 |
| Example 3 | 107.0 | 99.0 |
| Example 4 | 109.6 | 102.0 |
| Comp.Ex. 1 | 99.5 | 83.0 |
| Comp.Ex. 2 | 101.0 | 88.7 |
| At the time of production: 115.0% | ||
As is evident from Table 7 and Table 8, vitamin B₁ and vitamin B₁₂ in each liquid preparation of complex vitamin for internal use according to this invention retained high stability.
Claims (7)
- A stable liquid preparation of complex vitamin for internal use, said preparation containing vitamin B₁ and vitamin B₁₂, comprising a sugar alcohol as a sweetening agent, the pH of said preparation having been adjusted to 3.5 to 4.5.
- The preparation according to claim 1, wherein citric, malic, tartaric or succinic acid or a salt thereof has been used as a pH regulator in an amount not greater than 0.5 g per preparation.
- The preparation according to claim 1, wherein said sugar alcohol is xylitol, maltitol or sorbitol.
- The preparation according to claim 3, wherein citric, malic, tartaric or succinic acid or a salt thereof has been used as a pH regulator in an amount not greater than 0.5 g per preparation.
- The preparation according to claim 1, wherein vitamin B₁ is thiamine or a derivative thereof or a salt of thiamine or the thiamine derivative; and vitamin B₁₂ is cyanocobalamin.
- The preparation according to claim 5, wherein citric, malic, tartaric or succinic acid or a salt thereof has been used as a pH regulator in an amount not greater than 0.5 g per preparation.
- The preparation according to claim 5, wherein said sugar alcohol is xylitol, maltitol or sorbitol.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP256767/93 | 1993-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1016410A true HK1016410A (en) | 1999-10-29 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2274440C2 (en) | Compositions stimulating hair growth | |
| EP1335747B1 (en) | A composition of sodium channel blocking compound | |
| EP2649993B1 (en) | Stabilizer of acetaminophen | |
| EP2309983B1 (en) | Pharmaceutical form comprising tetrahydrobiopterin | |
| EP0648486B1 (en) | Stable liquid preparation of a vitamin complex for internal use | |
| EP1391202B1 (en) | Liquid drug preparations | |
| HK1016410A (en) | Stable liquid preparation of a vitamin complex for internal use | |
| JP2000007561A (en) | Ambroxol hydrochloride aqueous solution preparation | |
| EP3582765B1 (en) | Midodrine hydrochloride oral solution and uses thereof | |
| DE68912740T2 (en) | Acyclic derivatives with diuretic properties. | |
| JP2012025676A (en) | Liquid medicine containing sumatriptan succinate for internal use | |
| EP0906913A1 (en) | Pteridinderivatives as NO synthase inhibitors | |
| JPH11171793A (en) | Vitamin B1 compound liquid | |
| DE2841170A1 (en) | Hypnotic drug contg. L-tryptophan - and cpds. blocking chemical bonding of latter on serum protein, and also L-tryptophan pyrrolase inhibitors | |
| JPS6219535A (en) | Lysozyme syrup agent | |
| JP2001131070A (en) | Liquid composition containing riboflavin | |
| DE60219620T2 (en) | L-ASCORBIC ACID 2-O-MALEIC ACID-A-TOCOPHEROLDIESTER-1-PROPANOL ADDUCT AND METHOD FOR THE PRODUCTION THEREOF | |
| JP6633896B2 (en) | Biotin-containing solution | |
| JPS63313725A (en) | Syrup agent | |
| DE69904021T2 (en) | LIQUID PHARMACEUTICAL PREPARATION CONTAINING ZOTEPIN | |
| JP2002322062A (en) | Liquid for internal use | |
| DE2737735C3 (en) | Medicines containing pirbutero and hydroxyzine | |
| JP2000247883A (en) | Liquid agent for internal use containing dihydropyridine- based compound | |
| JP2003171283A (en) | Xanthine oxidase inhibitor | |
| DE3687448T2 (en) | USE OF 6H-7,8-DIHYDROTHIAPYRANO (3,2D) PYRIMIDINES FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR USE AS HYPOGLYKAEMIC AGENTS OR AS A WEIGHTING AGENT FOR FAT-ADHESIVE PATIENTS. |